Taysha Gene Therapies Files 8-K

Ticker: TSHA · Form: 8-K · Filed: May 28, 2025 · CIK: 1806310

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

TL;DR

Taysha Gene Therapies filed an 8-K on 5/28/25 covering Reg FD, other events, and financials.

AI Summary

Taysha Gene Therapies, Inc. filed an 8-K on May 28, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company's principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas.

Why It Matters

This 8-K filing provides updates on Taysha Gene Therapies' corporate activities and regulatory disclosures, which are important for investors to monitor the company's compliance and operational status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting various corporate events and disclosures, not indicating any immediate material adverse changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Taysha Gene Therapies, Inc.?

The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, covering Regulation FD disclosures, other events, and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 28, 2025.

Where are Taysha Gene Therapies, Inc.'s principal executive offices located?

The principal executive offices of Taysha Gene Therapies, Inc. are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Taysha Gene Therapies, Inc. is 84-3199512.

What is the Standard Industrial Classification code for Taysha Gene Therapies, Inc.?

The Standard Industrial Classification code for Taysha Gene Therapies, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing